Revolution Medicines, Inc. RVMD

Healthcare SIC 2836 - Biological Products, (No Diagnostic Substances) NAICS Manufacturing › Chemical Manufacturing › Pharmaceutical and Medicine Manufacturing › Biological Product (except Diagnostic) Manufacturing derived Nasdaq

We are a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. We possess sophisticated structure-based drug discovery capabilities built upon deep chemical biology and cancer pharmacology know-how and innovative, proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites. Guided by our understanding of genetic drivers and adaptive resistance mechanisms in cancer, we deploy precision medicine approaches to inform innovative monotherapy and combination regimens. Our research and development pipeline comprises inhibitors that bind directly to RAS variants (RAS(ON) Inhibitors) that are designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or other therapeutic agents.

Last close 186.99 2026-10-23
Market cap $40.08B 2026-06-30 share count
52-week range 55.40 - 224.31

Valuation FY2025 figures against the last close

P/S—
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS-5.95

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Revenue $0$0$11.6M$35.4M$29.4M$43.0M$50.0M$20.2M—
R&D $987.3M$592.2M$423.1M$253.1M$186.9M$132.3M$91.8M$51.1M—
SG&A $195.0M$97.3M$75.6M$40.6M$30.4M$21.4M$12.4M$9.4M—
Total operating expenses $1.18B$689.5M$498.8M$293.7M$217.4M$153.7M$104.2M$60.5M—
Operating income -$1.18B-$689.5M-$487.2M-$258.3M-$188.0M-$110.7M-$54.1M-$40.3M—
Interest expense $24.2M$0$0$0$12.0K$71.0K$106.0K$116.0K—
Pre-tax income -$1.13B-$600.8M-$439.9M-$249.1M-$187.1M-$108.5M-$52.0M-$41.8M—
Income tax $0$753.0K$3.5M$420.0K$0$371.0K$4.4M——
Net income -$1.13B-$600.0M-$436.0M-$249.0M-$187.0M-$108.2M-$47.7M-$41.8M—
EPS, basic -5.95-3.58-3.86-3.08-2.57-2.01———
EPS, diluted -5.95-3.58-3.86-3.08-2.57-2.01-22.33-21.24—
Shares, diluted (wtd. avg.) 190.1M167.7M113.1M80.6M72.8M54.9M———

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash and equivalents $383.7M$543.1M$696.1M$161.4M$108.5M$104.3M$16.7M$69.6M—
Short-term investments $1.64B$1.75B$1.16B$483.5M$468.6M$336.5M$106.1M——
Total current assets $2.08B$2.33B$1.88B$660.2M$589.8M$454.1M$134.0M——
Property, plant and equipment $33.2M$24.3M$22.9M$18.7M$11.5M$8.9M$7.1M——
Goodwill $14.6M$14.6M$14.6M$14.6M$14.6M$14.6M$14.6M——
Other intangibles $55.8M$56.7M$57.7M$58.8M$59.9M$60.9M$62.0M——
Total assets $2.35B$2.56B$2.06B$811.9M$738.0M$567.4M$220.5M——
Accounts payable $64.6M$54.4M$61.8M$21.3M$14.1M$12.6M$11.4M——
Total current liabilities $290.4M$163.9M$143.9M$62.0M$60.4M$47.2M$43.1M——
Total liabilities $723.2M$293.1M$235.5M$126.7M$135.4M$92.7M$68.0M——
Retained earnings -$2.87B-$1.74B-$1.14B-$701.3M-$452.6M-$265.5M-$157.4M——
Total equity $1.63B$2.27B$1.83B$685.2M$602.6M$474.7M-$152.6M-$108.4M-$67.7M

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Operating cash flow -$897.7M-$557.4M-$350.6M-$224.4M-$147.2M-$100.1M-$49.6M$1.2M—
Depreciation and amortisation $7.8M$6.6M$5.0M$4.0M$3.1M$2.6M$2.3M$1.6M—
Stock-based compensation $118.4M$79.2M$61.8M$31.2M$20.7M$8.9M$3.2M$855.0K—
Capital expenditure $16.0M$10.3M$7.7M$10.8M$6.5M$2.9M$2.6M$1.5M—
Investing cash flow $118.1M-$554.4M-$342.6M-$24.1M-$142.1M-$234.2M-$102.0M-$1.3M—
Financing cash flow $621.5M$959.4M$1.23B$301.4M$294.2M$422.8M$98.7M$60.8M—
Dividends paid —————$0———

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-182453.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. -1.5B -1B -500M 0 500M Revenue, FY2018: 20.2M Net income, FY2018: -41.8M Revenue, FY2019: 50M Net income, FY2019: -47.7M Revenue, FY2020: 43M Net income, FY2020: -108.2M Revenue, FY2021: 29.4M Net income, FY2021: -187M Revenue, FY2022: 35.4M Net income, FY2022: -249M Revenue, FY2023: 11.6M Net income, FY2023: -436M Revenue, FY2024: 0 Net income, FY2024: -600M Revenue, FY2025: 0 Net income, FY2025: -1.1B FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue — $20.2M $50.0M $43.0M $29.4M $35.4M $11.6M $0 $0
Gross profit — — — — — — — — —
Net income — -$41.8M -$47.7M -$108.2M -$187.0M -$249.0M -$436.0M -$600.0M -$1.13B

Recent filings and events

  • Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
  • New debt or obligation The company has taken on debt or a comparable obligation. Item 2.03
  • Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
  • Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
  • Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
  • Shareholder vote The results of the annual meeting or a special vote. Item 5.07
  • Results announced Item 2.02
  • Material agreement signed Item 1.01
  • New debt or obligation Item 2.03
  • Other event Item 8.01
  • Other event Item 8.01
  • Other event Item 8.01

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 2836

TickerCompanyMarket capP/ERevenue growth
AMGN AMGEN INC $237.48B 30.9x 10.0%
GILD GILEAD SCIENCES, INC. $193.48B 23.0x 2.4%
MRNA Moderna, Inc. $79.89B — -39.9%
BIIB BIOGEN INC. $37.01B 28.5x 2.2%
EXEL EXELIXIS, INC. $15.99B 23.2x 7.0%
NBIX NEUROCRINE BIOSCIENCES INC $14.51B 30.6x 21.4%
HALO HALOZYME THERAPEUTICS, INC. $14.26B 49.1x 37.6%
TECH BIO-TECHNE Corp $11.38B 62.5x -0.4%